Sirolimus for treatment of kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon

Alaa M Alaqeel, Nuha A Alfurayh, Alanoud A Alhedyani, Saad M Alajlan, Alaa M Alaqeel, Nuha A Alfurayh, Alanoud A Alhedyani, Saad M Alajlan

No abstract available

Keywords: KHE, kaposiform hemangioendothelioma; KMP, Kasabach-Merritt phenomenon; Kasabach-Merritt phenomenon; case report; kaposiform hemangioendothelioma; sirolimus; treatment; vascular.

Figures

Fig 1
Fig 1
Kaposiform hemangioendothelioma. A huge mass involving right side of the face, almost obscuring the right eye, with extension to the upper chest before sirolimus therapy.
Fig 2
Fig 2
MRI with fat suppression before sirolimus therapy showed extensive bright areas involving the right side of the face, from skin almost reaching the airways.
Fig 3
Fig 3
After 15 months of sirolimus therapy.
Fig 4
Fig 4
MRI with fat suppression after 15 months of sirolimus therapy showed a remarkable 90% to 95% reduction of the volume of the enhancing tissue with few residual areas of high signal in the skin and deeper tissue.

References

    1. Fernández Y., Bernabeu-Wittel M., García-Morillo J.S. Kaposiform hemangioendothelioma. Eur J Intern Med. 2009;20(2):106–113.
    1. Croteau S.E., Liang M.G., Kozakewich H.P. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr. 2013;162(1):142–147.
    1. DeFatta R.J., Verret D.J., Adelson R.T., Gomez Ana, Myers L.L. Kaposiform hemangioendothelioma: case report and literature review. Laryngoscope. 2005;115(10):1789–1792.
    1. Kai L., Wang Z., Yao W., Dong K., Xiao X. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma. J Cancer Res Clin Oncol. 2014;140(3):471–476.
    1. Cyrulnik A.A., Dawkins M.C., Smalberger G.J. Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome mistaken for child abuse in a newborn. Cutis. 2014;93(3):E17–E20.
    1. Vivas-Colmenares G.V., Ramirez-Villar G.L., Bernabeu-Wittel J., Matute de Cardenas J.A., Fernandez-Pineda I. The importance of early diagnosis and treatment of kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon. Dermatol Pract Concept. 2015;5(1):91–93.
    1. Drolet B.A., Trenor C.C., Brandão L.R. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr. 2013;163(1):285–291.
    1. Wang Z., Li K., Dong K., Xiao X., Zheng S. Refractory Kasabach–Merritt phenomenon successfully treated with sirolimus, and a mini-review of the published work. J Dermatol. 2015;42(4):401–404.
    1. Chiu Y.E., Drolet B.A., Blei F. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach–Merritt phenomenon. Pediatr Blood Cancer. 2012;59(5):934–938.
    1. Kasabach H.H., Merritt K.K. Capillary hemangioma with extensive purpura: report of a case. Am J Dis Child. 1940;59(5):1063–1070.
    1. Jahnel J., Lackner H., Reiterer F., Urlesberger B., Urban C. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus. Klin Pädiatr. 2012;224(6):395–397.
    1. Uno T., Ito S., Nakazawa A., Miyazaki O., Mori T., Terashima K. Successful treatment of kaposiform hemangioendothelioma with everolimus. PediatrBlood Cancer. 2015;62(3):536–538.
    1. Blatt J., Stavas J., Moats-Staats B., Woosley J., Morrell D. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer. 2010;55(7):1396–1398.
    1. Hammill A.M., Wentzel M., Gupta A. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57(6):1018–1024.
    1. Vlahovic A.M., Vlahovic N.S., Haxhija E.Q. Sirolimus for the treatment of a massive capillary-lymphaticovenous malformation: a case report. Pediatrics. 2015;136(2):e513–e516.
    1. Lackner H., Karastaneva A., Schwinger W. Sirolimus for the treatment of children with various complication vascular anomalies. Eur J Pediatr. 2015;174(12):1579–1584.
    1. Fogel A.L., Hill S., Teng J.M. Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology. J Am Acad Dermatol. 2015;72(5):879–889.
    1. Kim D., Benjamin L., Wysong A., Hovsepian D., Teng J. Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone. Dermatol Ther. 2015;28(4):218–221.
    1. Rössler J., Braunschweiger F., Schill T. [Medication-based therapy of infantile hemangioma and lymphatic malformations] HNO. 2014;62(1):12–18.
    1. Margolin J.F., Soni H.M., Pimpalwar S. Medical therapy for pediatric vascular anomalies. Semin Plast Surg. 2014;28(2):79–86.
    1. Schroeder U., Lauten M., Stichtenoth G., Gebhard M.P., Buchholz M., Kaiser M.M. Laryngomalacia and complicated, life-threatening mTOR-positive kaposiform hemangioendothelioma cured by supraglottoplasty and sirolimus. Klin Padiatr. 2014;226(6-7):362–368.
    1. Adams D.M., Trenor C.C., 3rd, Hammill A.M. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics. 2016;137(2):e20153257.
    1. Mukerji S.S., Osborn A.J., Roberts J., Valdez T.A. Kaposiform hemangioendothelioma (with Kasabach Merritt syndrome) of the head and neck: case report and review of the literature. Int J Pediatr Otorhinolaryngol. 2009;73(10):1474–1476.

Source: PubMed

3
Subskrybuj